MDGL logo

Madrigal Pharmaceuticals, Inc. Stock Price

NasdaqGS:MDGL Community·US$12.3b Market Cap
  • 3 Narratives written by author
  • 1 Comments on narratives written by author
  • 37 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

MDGL Share Price Performance

US$531.52
91.45 (20.78%)
​
US$678.71
Fair Value
US$531.52
91.45 (20.78%)
21.7% undervalued intrinsic discount
US$678.71
Fair Value
Price US$531.52
AnalystConsensusTarget US$678.71
AnalystLowTarget US$550.00
AnalystHighTarget US$904.36

MDGL Community Narratives

Fair Value
·
Fair Value US$678.71 21.7% undervalued intrinsic discount

EU Expansion and Combination Therapies Will Drive Future Opportunity

0users have liked this narrative
0users have commented on this narrative
14users have followed this narrative
Fair Value
·
Fair Value US$550 3.4% undervalued intrinsic discount

US Pricing Pressure And European Payers Will Erode Margins

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Fair Value
·
Fair Value US$904.36 41.2% undervalued intrinsic discount

Rising Obesity And Aging Trends Will Drive NASH Therapy Adoption

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
MDGL logo
Madrigal Pharmaceuticals
21.7% undervalued intrinsic discount

EU Expansion and Combination Therapies Will Drive Future Opportunity

View narrative
Updated 17 Jun
Read Narrative
MDGL logo
Madrigal Pharmaceuticals
3.4% undervalued intrinsic discount

US Pricing Pressure And European Payers Will Erode Margins

View narrative
Updated 3 Jun
Read Narrative
MDGL logo
Madrigal Pharmaceuticals
41.2% undervalued intrinsic discount

Rising Obesity And Aging Trends Will Drive NASH Therapy Adoption

View narrative
Updated 2 Mar
Read Narrative

Trending Discussion

No trending discussion available.

Updated Narratives

MDGL logo

MDGL: Future Upside Will Rely On Expanding MASH Patient Treatment Pool

Fair Value: US$678.71 21.7% undervalued intrinsic discount
14 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
MDGL logo

MDGL: MASH Eligibility And Upcoming EASL Data Will Shape Bullish Outlook

Fair Value: US$550 3.4% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
MDGL logo

MDGL: MASH Franchise And DGAT2 Combo Plans Will Drive Future Upside

Fair Value: US$904.36 41.2% undervalued intrinsic discount
3 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Exceptional growth potential and undervalued.

1 Risk
3 Rewards
View Full Analysis

Madrigal Pharmaceuticals, Inc. Key Details

US$1.3b

Revenue

US$109.4m

Cost of Revenue

US$1.2b

Gross Profit

US$1.5b

Other Expenses

-US$325.1m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
-14.07
91.48%
-25.32%
65.1%
View Full Analysis

About MDGL

Founded
2016
Employees
915
CEO
William Sibold
WebsiteView website
www.madrigalpharma.com

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.

Recent MDGL News & Updates

Recent updates

No updates

Madrigal Pharmaceuticals, Inc. Competitors

REGN logo

Regeneron Pharmaceuticals

Symbol: NasdaqGS:REGN
Market cap: US$78.4b
MRNA logo

Moderna

Symbol: NasdaqGS:MRNA
Market cap: US$61.5b
NTRA logo

Natera

Symbol: NasdaqGS:NTRA
Market cap: US$53.2b
TEVA logo

Teva Pharmaceutical Industries

Symbol: NYSE:TEVA
Market cap: US$45.4b
View more competitors